Glaus C - Search Results

1

In vivo evaluation of (64)Cu-labeled magnetic nanoparticles as a dual-modality PET/MR imaging agent.

Glaus C, Rossin R, Welch MJ, Bao G. Glaus C, et al. Bioconjug Chem. 2010 Apr 21;21(4):715-22. doi: 10.1021/bc900511j. Bioconjug Chem. 2010. PMID: 20353170 Free PMC article.

2

Gold nanocages as photothermal transducers for cancer treatment.

Chen J, Glaus C, Laforest R, Zhang Q, Yang M, Gidding M, Welch MJ, Xia Y. Chen J, et al. Among authors: glaus c. Small. 2010 Apr 9;6(7):811-7. doi: 10.1002/smll.200902216. Small. 2010. PMID: 20225187 Free PMC article.

3

Inorganic nanoparticle-based contrast agents for molecular imaging.

Cho EC, Glaus C, Chen J, Welch MJ, Xia Y. Cho EC, et al. Among authors: glaus c. Trends Mol Med. 2010 Dec;16(12):561-73. doi: 10.1016/j.molmed.2010.09.004. Epub 2010 Nov 10. Trends Mol Med. 2010. PMID: 21074494 Free PMC article. Review.

4

Gold Nanocages: A Novel Class of Multifunctional Nanomaterials for Theranostic Applications.

Chen J, Yang M, Zhang Q, Cho EC, Cobley CM, Kim C, Glaus C, Wang LV, Welch MJ, Xia Y. Chen J, et al. Among authors: glaus c. Adv Funct Mater. 2010 Nov 9;20(21):3684-3694. doi: 10.1002/adfm.201001329. Epub 2010 Oct 4. Adv Funct Mater. 2010. PMID: 33907543 Free PMC article.

5

Launch and Postlaunch Price Developments of New Drugs in the US, Germany, and Switzerland.

Laube Y, Serra-Burriel M, Glaus CCEG, Vokinger KN. Laube Y, et al. Among authors: glaus cceg. JAMA Health Forum. 2024 Nov 1;5(11):e244461. doi: 10.1001/jamahealthforum.2024.4461. JAMA Health Forum. 2024. PMID: 39601756 Free article.

6

WHO shapes priorities for medicines? An analysis of the applicants and decision makers within the historical evolution of the WHO Model Lists of Essential Medicines.

Jenei K, Glaus CEG, Vokinger KN. Jenei K, et al. Among authors: glaus ceg. Lancet. 2024 Oct 5;404(10460):1365-1374. doi: 10.1016/S0140-6736(24)01549-6. Lancet. 2024. PMID: 39368844 Review.

7

Time From Approval to Reimbursement of New Drugs: A Comparative Analysis Between the United States, England, Germany, France, and Switzerland (2011-2022).

Glaus CEG, Serra-Burriel M, Dusetzina SB, Vokinger KN. Glaus CEG, et al. Ann Intern Med. 2024 Oct;177(10):1442-1444. doi: 10.7326/ANNALS-24-00614. Epub 2024 Sep 3. Ann Intern Med. 2024. PMID: 39222511 No abstract available.

8

Defining 'therapeutic value' of medicines: a scoping review.

Glaus CEG, Kloeti A, Vokinger KN. Glaus CEG, et al. BMJ Open. 2023 Dec 18;13(12):e078134. doi: 10.1136/bmjopen-2023-078134. BMJ Open. 2023. PMID: 38110384 Free PMC article. Review.

9

Approval and therapeutic value of gene therapies in the US and Europe.

Vokinger KN, Glaus CEG, Kesselheim AS. Vokinger KN, et al. Among authors: glaus ceg. Gene Ther. 2023 Nov;30(10-11):756-760. doi: 10.1038/s41434-023-00402-4. Epub 2023 Nov 8. Gene Ther. 2023. PMID: 37935853

10

Regulatory Review Duration and Differences in Submission Times of Drugs in the United States and Europe, 2011 to 2020.

Vokinger KN, Serra-Burriel M, Glaus CEG, Rohr UP, Hwang TJ, Dalla Torre di Sanguinetto S, Kesselheim AS. Vokinger KN, et al. Among authors: glaus ceg. Ann Intern Med. 2023 Oct;176(10):1413-1418. doi: 10.7326/M23-0623. Ann Intern Med. 2023. PMID: 37844306 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

23 results

Search Page

Filters